Shore Capital Reaffirms Buy Rating for AstraZeneca (LON:AZN)

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN - Free Report) in a report released on Friday, Marketbeat reports.

Several other brokerages also recently weighed in on AZN. Deutsche Bank Aktiengesellschaft reiterated a sell rating on shares of AstraZeneca in a research note on Tuesday, March 12th. Berenberg Bank restated a buy rating on shares of AstraZeneca in a research report on Wednesday, March 13th. UBS Group reduced their price objective on AstraZeneca from £107 ($134.32) to GBX 9,900 ($124.28) and set a sell rating on the stock in a research report on Monday, February 12th. JPMorgan Chase & Co. reiterated an overweight rating on shares of AstraZeneca in a research report on Thursday. Finally, Jefferies Financial Group restated a hold rating and set a £110 ($138.09) price target on shares of AstraZeneca in a research note on Friday, February 16th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of £117.13 ($147.03).

AstraZeneca Stock Performance

Shares of AZN traded down GBX 116 ($1.46) during mid-day trading on Friday, hitting £106.20 ($133.32). 1,284,584 shares of the company's stock were exchanged, compared to its average volume of 2,279,785. AstraZeneca has a fifty-two week low of GBX 9,461 ($118.77) and a fifty-two week high of £123.92 ($155.56). The firm has a market capitalization of £164.61 billion, a P/E ratio of 3,516.56, a P/E/G ratio of 0.87 and a beta of 0.17. The business's 50 day moving average is £102.89 and its two-hundred day moving average is £104.38. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70.

AstraZeneca Increases Dividend

The business also recently declared a dividend, which was paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd were given a GBX 156 ($1.96) dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a dividend yield of 1.49%. This is a boost from AstraZeneca's previous dividend of $71.80. AstraZeneca's payout ratio is currently 7,549.67%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.